Article metrics
PDF
Other content recommended for you
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group
- Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies
- Changes to anti-JCV antibody levels in a Swedish national MS cohort
- Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications
- Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab
- Natalizumab: safety and risk in patients with relapsing-remitting multiple sclerosis
- JC viral loads in patients with Crohn’s disease treated with immunosuppression: can we screen for elevated risk of progressive multifocal leukoencephalopathy?
- Update on disease-modifying therapies for multiple sclerosis
- Extended interval dosing of natalizumab in multiple sclerosis